DSpace Repository

Efficacy and Safety of the Use of SGLT2 Inhibitors in Patients on Incremental Hemodialysis: Maximizing Residual Renal Function, Is There a Role for SGLT2 Inhibitors?

Show simple item record

dc.contributor.author De La Flor, José C.
dc.contributor.author Villa, Daniel
dc.contributor.author Cruzado, Leónidas
dc.contributor.author Apaza, Jacqueline
dc.contributor.author Valga, Francisco
dc.contributor.author Zamora, Rocío
dc.contributor.author Marschall, Alexander
dc.contributor.author Cieza Terrones, Michael Javier
dc.contributor.author Deira, Javier
dc.contributor.author Rodeles, Miguel
dc.coverage.spatial Hospital Central de la Defensa Gómez Ulla, Madrid, España
dc.date.accessioned 2023-09-06T20:45:10Z
dc.date.available 2023-09-06T20:45:10Z
dc.date.issued 2023
dc.identifier.uri https://hdl.handle.net/20.500.12866/14095
dc.description.abstract SGLT-2i are the new standard of care for diabetic kidney disease (DKD), but previous studies have not included patients on kidney replacement therapy (KRT). Due to their high risk of cardiovascular, renal complications, and mortality, these patients would benefit the most from this therapy. Residual kidney function (RKF) conveys a survival benefit and cardiovascular health among hemodialysis (HD) patients, especially those on incremental hemodialysis (iHD). We retrospectively describe the safety and efficacy of SGLT2i regarding RKF preservation in seven diabetic patients with different clinical backgrounds who underwent iHD (one or two sessions per week) during a 12-month follow-up. All patients preserved RKF, measured as residual kidney urea clearance (KrU) in 24 h after the introduction of SGLT2i. KrU levels improved significantly from 4.91 ± 1.14 mL/min to 7.28 ± 1.68 mL/min at 12 months (p = 0.028). Pre-hemodialysis blood pressure improved 9.95% in mean systolic blood pressure (SBP) (p = 0.015) and 10.95% in mean diastolic blood pressure (DBP) (p = 0.041); as a result, antihypertensive medication was modified. Improvements in blood uric acid, hemoglobin A1c, urine albumin/creatinine ratio (UACR), and 24 h proteinuria were also significant. Regarding side effects, two patients developed uncomplicated urinary tract infections that were resolved. No other complications were reported. The use of SGLT2i in our sample of DKD patients starting iHD on a 1-2 weekly regimen appears to be safe and effective in preserving RKF. en_US
dc.language.iso eng
dc.publisher MDPI
dc.relation.ispartofseries Biomedicines
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Incremental hemodialysis en_US
dc.subject Sodium/glucose cotransporter-2 inhibitor en_US
dc.subject Residual kidney function en_US
dc.subject End stage renal disease en_US
dc.subject Diabetic kidney disease en_US
dc.subject Kidney replacement therapy en_US
dc.subject.mesh Diálisis Renal
dc.subject.mesh Inhibidores del Cotransportador de Sodio-Glucosa 2
dc.subject.mesh Pruebas de Función Renal
dc.subject.mesh Fallo Renal Crónico
dc.subject.mesh Nefropatías Diabéticas
dc.subject.mesh Terapia de Reemplazo Renal
dc.title Efficacy and Safety of the Use of SGLT2 Inhibitors in Patients on Incremental Hemodialysis: Maximizing Residual Renal Function, Is There a Role for SGLT2 Inhibitors? en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.3390/biomedicines11071908
dc.relation.issn 2227-9059

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


My Account